Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice
Journal Title: OncoReview - Year 2014, Vol 4, Issue 4
Abstract
Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced stage. Currently, we distinguish several types of amyloidosis. Cardiac amyloidosis may be caused by cancer, chronic inflammation, genetic factors and by aging related processes. Overproduction of amyloidogenic proteins by tumor cells has a key role in the pathogenesis of immunoglobulin light chain amyloidosis. Cardiovascular complications in patients with amyloidosis can be induced by insoluble deposits of misfolded proteins or by direct toxic effects of amyloidogenic molecules on cardiomyocytes and endothelial cells.In this review we focus mainly on pathophysiological mechanisms of cardiac amyloidosis, classification of cardiac amyloidosis types and their cardiovascular manifestations.
Authors and Affiliations
Beata Mladosievicova, Zuzana Poljak, Olja El-Hassoun, Lubica Roziakova, Andrea Carter
Keywords
Related Articles
- EP ID EP67765
- DOI -
- Views 176
- Downloads 0
Knowledge about prevention, risk factors and treatment in women with diagnosed breast cancer. Whether the disease affects their healthy behaviour?
Objective. The assessment of knowledge about prevention and risk factors of women with diagnosed breast cancer.Material and methods. The study involved 100 women aged from 28 to 82 years (median 56.2 years) who were trea...
Targeted therapies in neuroendocrine neoplasms
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biologica...
Everolimus in clinical practice. Review of German non-interventional study of everolimus in metastatic renal cell cancer after failure of initial tyrosine kinase inhibitor therapy
Everolimus is a standard for treatment of anti-vascular endothelial growth factor (VEGF)-refractory patients with metastatic renal cell carcinoma (mRCC). A German study documented mRCC patient treated everolimus from 79...
Cardiooncological balance in a 75-year-old male with a hepatocellular carcinoma CS IV and a congestive heart failure NYHA III „de novo”
The case reports about a 75-years-old man without a previous medical history, in whom a heart failure NYHA III de novo was diagnosed together with persistent atrial fibrillation and hepatocellular carcinoma in clinical s...
Nowe możliwości celowanego leczenia uogólnionego raka piersi z ekspresją receptorów hormonalnych
Badania molekularne wykazały, że rak piersi jest grupą heterogennych chorób o różnych cechach biologicznych i różnym rokowaniu. Z klinicznego punktu widzenia raka piersi podzielić można na trzy różne typy o odmiennej pod...